Hemoglobins from Wistar Rat:

Brunori, Maurizio; Condò, Saverio G.; Bellelli, Andrea; Giardina, Bruno

doi:10.1111/j.1432-1033.1982.tb07071.x

Cited by 11 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An instructive example is represented by rat RBC. Rat hemoglobin displays a remarkable low solubility and rapidity of crystallization . As a consequence, processing rat red cells results in very low cell recovery and abundant hemoglobin precipitation in insoluble irreversible forms.…”

Section: Erythrocytes From Different Animal Species and Preclinical Smentioning

confidence: 99%

“…Rat hemoglobin displays a remarkable low solubility and rapidity of crystallization. 101 As a consequence, processing rat red cells results in very low cell recovery and abundant hemoglobin precipitation in insoluble irreversible forms. A further issue affecting cell recovery upon the encapsulation procedures is represented by the ability of the membrane to be resealed.…”

Section: Erythrocytes From Different Animal Species and Preclinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Recently optimized technologies that permit the reversible opening of nanopores across the red blood cell membrane, give the extraordinary opportunity for reengineering human erythrocytes to be used in different biomedical applications, both for therapeutic and diagnostic purposes. Engineered erythrocytes have been exploited as a system for the controlled release of drugs in circulation upon encapsulation of prodrugs or small molecules; as bioreactors when they are endowed of recombinant enzymes able to catalyze the conversion of toxic metabolite into inert products; as drug targeting system for the delivery of compounds to the reticuloendothelial system inducing proper senescent signals on the drug-loaded erythrocyte membrane; as carrier of contrasting agents for diagnostic procedures. Preclinical development of these different applications has taken advantage from the use of proper animal models whose erythrocytes can be reengineered as the human ones or the encapsulation procedures can be adapted on the basis of their specific erythrocyte biological features. Successful results, obtained both in vitro and in preclinical studies, have prompted several clinicians to start pilot clinical investigations in different conditions and some new companies to start the industrialization of selected loading technologies and to initiate clinical development programs. This short review summarizes the key features that, to the best of our knowledge, have been crucial to advance the products toward regulatory clinical approval making reengineering of erythrocytes a modality to treat patients with limited or absent therapeutic options. WIREs Nanomed Nanobiotechnol 2017, 9:e1454. doi: 10.1002/wnan.1454 For further resources related to this article, please visit the WIREs website.

show abstract

Section: Erythrocytes From Different Animal Species and Preclinical Smentioning

confidence: 99%

Section: Erythrocytes From Different Animal Species and Preclinical Studiesmentioning

confidence: 99%

Reengineering red blood cells for cellular therapeutics and diagnostics

Pierigé

Bigini

Rossi

et al. 2017

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…12 In the rat, hemoglobin crystals are fairly common and are thought to be an intermediate breakdown product of hemoglobin. 4,15 In our case, the eosinophilic, refractile appearance of the crystals and unusual location sparked investigation into these and other extracellular eosinophilic deposits seen in histopathology. Our investigation included reports of sclerotic collagen, amianthoid fibers, skeinoid fibers, and Charcot-Leyden crystals from various species (Table 1).…”

mentioning

confidence: 78%

Charcot–Leyden crystals: do they exist in veterinary species? A case report and literature review

et al. 2017

View full text Add to dashboard Cite

The Charcot-Leyden crystal (CLC) is a major human eosinophil protein that readily crystallizes; these crystals are common in eosinophilic diseases. Although anecdotal existence of these crystals is known in veterinary pathology, definitive reports do not exist, to our knowledge. We identified eosinophilic crystals in a laryngeal myxosarcoma from a 2-y-old, spayed female, Labrador Retriever dog that were tentatively interpreted as CLCs. However, Ziehl-Neelsen acid-fast stain was negative, arguing against CLCs. The crystals stained red with Masson trichrome, precluding collagen. Periodic acid-Schiff and alcian blue were negative. The crystals stained positively with Okajima, and no myoglobin immunoreactivity was detected, supporting their identity as hemoglobin crystals. In the absence of a hematologic abnormality, these crystals were interpreted to be abnormal hemoglobin breakdown products. Protein sequence comparison was pursued to determine whether a protein similar to CLC exists in mammals. Only 3 nonhuman primate species, the Sumatran orangutan ( Pongo abelii), rhesus macaque ( Macaca mulatta), and cynomolgus monkey ( Macaca fascicularis), had a sequence similarity of >80%. Of the crystal-forming residues, 12 of 54 (22%) were different in the Sumatran orangutan and 15 of 54 (28%) were different in the Macaca spp., which may affect the crystallization process. The lack of reports of CLCs in nonhuman species and our results collectively suggest that CLCs are human-specific.

show abstract

“…As for blood samples, the protocol for human samples is described, but it can be applied to blood samples from virtually all animal species too. Nevertheless, since rat hemoglobin can form precipitates when handled at low pH (Brunori et al 1982 ), a specific procedure is described accordingly.…”

Section: Protocolmentioning

confidence: 99%

Measurement of S-glutathionylated proteins by HPLC

et al. 2021

View full text Add to dashboard Cite

S-glutathionylated proteins (GSSP), i.e., protein-mixed disulfides with glutathione (GSH), are considered a suitable biomarker of oxidative stress. In fact, they occur within cells at low level and their concentration increases markedly under pro-oxidant conditions. Plasma is something different, since it is physiologically rich in S-thiolated proteins (RSSP), i.e., protein-mixed disulfides with various types of low molecular mass thiols (LMM-SH). However, albumin, which is largely the most abundant plasma protein, possesses a cysteine residue at position 34 that is mostly reduced (about 60%) under physiological conditions, but easily involved in the formation of additional RSSP in the presence of oxidants. The quantification of GSSP requires special attention to sample handling, since their level can be overestimated as a result of artefactual oxidation of GSH. We have developed the present protocol to avoid this methodological problem. Samples should be treated as soon as possible after their collection with the alkylating agent N-ethylmaleimide that masks –SH groups and prevents their oxidation. The GSH released from mixed disulfides by reduction with dithiothreitol is then labeled with the fluorescent probe monobromobimane and quantified by HPLC. The method can be applied to many different biological samples, comprising blood components, red blood cell plasma membrane, cultured cells, and solid organs from animal models.

show abstract

Hemoglobins from Wistar Rat:

Cited by 11 publications

References 13 publications

Reengineering red blood cells for cellular therapeutics and diagnostics

Reengineering red blood cells for cellular therapeutics and diagnostics

Charcot–Leyden crystals: do they exist in veterinary species? A case report and literature review

Measurement of S-glutathionylated proteins by HPLC

Contact Info

Product

Resources

About